Genprex to Present at NobleCon17 on January 19
January 14 2021 - 8:30AM
Business Wire
Presentation to Highlight the Company’s Recent
Progress on its Upcoming Clinical Trials for the Treatment of
Non-Small Cell Lung Cancer
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a
clinical-stage gene therapy company focused on developing
life-changing therapies for patients with cancer and diabetes,
today announced that the Company will present at the NobleCon17,
Noble Capital Markets’ Annual Investor Conference, taking place
virtually January 19-20. Genprex’s President and Chief Executive
Officer, Rodney Varner, will virtually deliver a company overview,
including recent progress made on its upcoming clinical trials, to
participating investors.
Event: NobleCon17 Presentation Date: Tuesday,
January 19 Presentation Time: 3:45 p.m. EST – Track 1
Registration Link: https://bit.ly/3oAVY1c
A high-definition, video webcast of the presentation will be
available for replay on the Company's website (www.genprex.com) for
a period of time following the conference, and the replay will also
be available as part of a complete catalog of presentations to be
rebroadcast on Channelchek at www.channelchek.com next month.
Noble Capital Markets recently released a report on Channelchek,
its small and microcap database titled, “The Most Studied Research,
Most Popular Videos, and Most Read Articles of 2020.” The report
reviewed Channelchek’s most popular content from 2020, and found
that a research note on Genprex took the number one spot for being
the most read research report of the year.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused
on developing life-changing therapies for patients with cancer and
diabetes. Genprex’s technologies are designed to administer
disease-fighting genes to provide new therapies for large patient
populations with cancer and diabetes who currently have limited
treatment options. Genprex works with world-class institutions and
collaborators to develop drug candidates to further its pipeline of
gene therapies in order to provide novel treatment approaches. The
Company’s lead product candidate, REQORSA™ (quaratusugene
ozeplasmid), is being evaluated as a treatment for non-small cell
lung cancer (NSCLC). REQORSA has a multimodal mechanism of action
that has been shown to interrupt cell signaling pathways that cause
replication and proliferation of cancer cells; re-establish
pathways for apoptosis, or programmed cell death, in cancer cells;
and modulate the immune response against cancer cells. REQORSA has
also been shown to block mechanisms that create drug resistance. In
January 2020, the U.S. Food and Drug Administration granted Fast
Track Designation for REQORSA for NSCLC in combination therapy with
osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR
mutations whose tumors progressed after treatment with osimertinib
alone.
For more information, please visit the Company’s web site at
www.genprex.com or follow Genprex on Twitter, Facebook and
LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effect of Genprex’s product candidates, alone and in
combination with other therapies, on cancer and diabetes, regarding
potential, current and planned clinical trials, regarding the
Company’s future growth and financial status and regarding our
commercial partnerships and intellectual property licenses. Risks
that contribute to the uncertain nature of the forward-looking
statements include the presence and level of the effect of our
product candidates, alone and in combination with other therapies,
on cancer; the timing and success of our clinical trials of
REQORSA™ immunogene therapy drug, alone and in combination with
targeted therapies and/or immunotherapies, and whether our other
potential product candidates, including GPX-002, our gene therapy
in diabetes, advance into clinical trials; the success of our
strategic partnerships, including those relating to manufacturing
of our product candidates; the timing and success at all of
obtaining FDA approval of REQORSA and our other potential product
candidates including whether we receive necessary approvals to
commence clinical trials or benefit from fast track or similar
regulatory designations; costs associated with developing our
product candidates, whether we identify and succeed in acquiring
other technologies and whether patents will ever be issued under
patent applications that are the subject of our license agreements
or otherwise. These and other risks and uncertainties are described
more fully under the caption “Risk Factors” and elsewhere in our
filings and reports with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. We
undertake no obligation to update such statements to reflect events
that occur or circumstances that exist after the date on which they
were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210114005185/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Sep 2023 to Sep 2024